Menu
Search
|

Menu

Close
X

Editas Medicine Inc EDIT.OQ (NASDAQ Stock Exchange Global Select Market)

24.11 USD
+0.14 (+0.58%)
As of 4:00 PM EDT
chart
Previous Close 23.97
Open 24.12
Volume 248,243
3m Avg Volume 335,962
Today’s High 24.59
Today’s Low 23.75
52 Week High 41.40
52 Week Low 17.90
Shares Outstanding (mil) 49.09
Market Capitalization (mil) 1,176.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.30 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
32
FY17
14
FY16
6
EPS (USD)
FY18
-2.341
FY17
-2.993
FY16
-3.031
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
36.85
8.91
Price to Book (MRQ)
vs sector
4.95
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
13.73
17.48
LT Debt to Equity (MRQ)
vs sector
13.73
13.83
Return on Investment (TTM)
vs sector
-30.50
12.19
Return on Equity (TTM)
vs sector
-49.50
13.29

EXECUTIVE LEADERSHIP

James Mullen
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Katrine Bosley
President, Director, Since 2019
Salary: $520,000.00
Bonus: $257,400.00
Cynthia Collins
interim Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Charles Albright
Chief Scientific Officer, Since 2016
Salary: $379,275.00
Bonus: $113,498.00
Gerald Cox
Chief Medical Officer, Since 2016
Salary: $100,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11 Hurley St
CAMBRIDGE   MA   02141-2110

Phone: +1617.4019000

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

SPONSORED STORIES